PubRank

Salim S Abdool Karim

Author PubWeight™ 126.85‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010 35.19
2 The impact of migration on HIV-1 transmission in South Africa: a study of migrant and nonmigrant men and their partners. Sex Transm Dis 2003 5.09
3 The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 2011 4.18
4 Health in South Africa: changes and challenges since 2009. Lancet 2012 3.44
5 Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One 2008 3.40
6 Achieving the health Millennium Development Goals for South Africa: challenges and priorities. Lancet 2009 3.35
7 Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 2009 2.70
8 Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol 2010 2.53
9 Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 2012 2.48
10 Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. J Infect Dis 2012 2.42
11 Microbicides & their implications in HIV prevention. Indian J Med Res 2010 2.36
12 The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol 2007 2.29
13 Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol 2011 2.26
14 The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J Womens Health (Larchmt) 2003 2.03
15 Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One 2011 1.99
16 Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol 2009 1.78
17 Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis 2012 1.73
18 Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog 2013 1.65
19 Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr 2011 1.31
20 Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr 2003 1.30
21 HIV incidence in young girls in KwaZulu-Natal, South Africa--public health imperative for their inclusion in HIV biomedical intervention trials. AIDS Behav 2012 1.26
22 Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J Infect Dis 2012 1.17
23 Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J Virol 2013 1.13
24 Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy. J Infect Dis 2013 1.12
25 The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention. Sex Transm Infect 2011 1.10
26 Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav 2014 1.09
27 APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS 2010 1.08
28 Adherence in the CAPRISA 004 tenofovir gel microbicide trial. AIDS Behav 2014 1.06
29 HIV prevalence among high school learners - opportunities for schools-based HIV testing programmes and sexual reproductive health services. BMC Public Health 2012 1.04
30 Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa. J Acquir Immune Defic Syndr 2006 1.03
31 The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol 2011 0.98
32 Association of polymorphisms in the LEDGF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression. AIDS 2011 0.97
33 Natural killer cell function in women at high risk for HIV acquisition: insights from a microbicide trial. AIDS 2012 0.96
34 Anaemia in acute HIV-1 subtype C infection. PLoS One 2008 0.96
35 Bacterial vaginosis and the risk of trichomonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis 2014 0.96
36 Diagnostic Accuracy of the Point-of-Care Xpert HIV-1 Viral Load Assay in a South African HIV Clinic. J Acquir Immune Defic Syndr 2016 0.96
37 When to start antiretroviral therapy during tuberculosis treatment? Curr Opin Infect Dis 2013 0.94
38 Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness. J Acquir Immune Defic Syndr 2015 0.93
39 Results of effectiveness trials of PRO 2000 gel: lessons for future microbicide trials. Future Microbiol 2010 0.93
40 Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses on HIV set point. J Virol 2013 0.92
41 Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial. J Infect Dis 2012 0.92
42 Antiretroviral therapy: challenges and options in South Africa. Lancet 2003 0.91
43 Incidence of Sexually Transmitted Infections among HIV-positive sex workers in KwaZulu-Natal, South Africa. Sex Transm Dis 2002 0.89
44 Y chromosome and HIV DNA detection in vaginal swabs as biomarkers of semen and HIV exposure in women. Sex Transm Dis 2014 0.88
45 Treatment of maternal syphilis in rural South Africa: effect of multiple doses of benzathine penicillin on pregnancy loss. Trop Med Int Health 2004 0.87
46 Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial. J Clin Microbiol 2013 0.87
47 The preventive misconception: experiences from CAPRISA 004. AIDS Behav 2014 0.86
48 Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting. AIDS Behav 2015 0.85
49 An AIDS-free generation? Science 2012 0.85
50 The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. S Afr Med J 2010 0.85
51 Trends in HIV Prevalence in Pregnant Women in Rural South Africa. J Acquir Immune Defic Syndr 2015 0.84
52 Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial. Trials 2014 0.83
53 Neither microbial translocation nor TLR responsiveness are likely explanations for preexisting immune activation in women who subsequently acquired HIV in CAPRISA 004. J Acquir Immune Defic Syndr 2013 0.83
54 A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin Investig Drugs 2012 0.82
55 Design challenges facing clinical trials of the effectiveness of new HIV-prevention technologies. AIDS 2012 0.82
56 Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection. Retrovirology 2014 0.82
57 Health-related quality of life dynamics of HIV-positive South African women up to ART initiation: evidence from the CAPRISA 002 acute infection cohort study. AIDS Behav 2014 0.82
58 Impact of antiretroviral therapy on health-related quality of life among South African women in the CAPRISA 002 acute infection study. AIDS Behav 2014 0.79
59 Monitoring microbicide gel use with real-time notification of the container's opening events: results of the CAPRISA Wisebag study. AIDS Behav 2014 0.79
60 Diverse approaches useful for microbicide trials. Nature 2007 0.79
61 Individualised motivational counselling to enhance adherence to antiretroviral therapy is not superior to didactic counselling in South African patients: findings of the CAPRISA 058 randomised controlled trial. AIDS Behav 2015 0.79
62 Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment. Antivir Ther 2015 0.78
63 TRIM5α and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment. J Virol 2014 0.78
64 HIV-positive status disclosure in patients in care in rural South Africa: implications for scaling up treatment and prevention interventions. AIDS Behav 2015 0.78
65 High rates of tuberculosis in patients accessing HAART in rural South Africa. J Acquir Immune Defic Syndr 2014 0.77
66 Low rifampicin concentrations in tuberculosis patients with HIV infection. J Infect Dev Ctries 2014 0.77
67 Metabolic Syndrome After HIV Acquisition in South African Women. J Acquir Immune Defic Syndr 2016 0.77
68 Top stories of 2008. The prospect of PrEP. AIDS Clin Care 2009 0.77
69 An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure. Clin Trials 2012 0.77
70 Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis-HIV-co-infected patients in resource-constrained settings. AIDS 2006 0.76
71 Tenofovir Gel to Prevent HSV-2 Infection. N Engl J Med 2015 0.75
72 Genital-Systemic Chemokine Gradients and the Risk of HIV Acquisition in Women. J Acquir Immune Defic Syndr 2017 0.75
73 Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial. Antiviral Res 2013 0.75
74 Association of Polymorphisms in the Regulatory Region of the Cyclophilin a Gene (PPIA) with Gene Expression and HIV/AIDS Disease Progression. J Acquir Immune Defic Syndr 2016 0.75
75 Report on the XIV International AIDS Conference. AIDS Clin Care 2002 0.75
76 Genital - Systemic chemokine gradients and the risk of HIV acquisition in women. J Acquir Immune Defic Syndr 2016 0.75
77 Update on pre-exposure prophylaxis. J Watch AIDS Clin Care 2011 0.75
78 HIV vaccine and microbicide trials turn a corner. We still don't have an effective vaccine or microbicide for the clinic, but two major trials this year brought us closer than we've ever been. J Watch AIDS Clin Care 2010 0.75
79 Challenging racial stereotyping of AIDS in South Africa with prevalence of HIV in pregnant women. S Afr Med J 2007 0.75
80 TMP-SMX prophylaxis reduces mortality among African patients on ART. J Watch AIDS Clin Care 2010 0.75
81 Top stories of 2004. DNA-MVA prime boost: another vaccine candidate bites the dust. AIDS Clin Care 2005 0.75
82 ART and pregnancy rates. J Watch AIDS Clin Care 2010 0.75
83 Antiretroviral pre-exposure prophylaxis; new hope and conundrums. J Watch AIDS Clin Care 2012 0.75
84 Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses. AIDS 2017 0.75
85 Report from the XVI International AIDS Conference. SMART and DART: intermittent antiretroviral treatment is suboptimal and should be avoided. AIDS Clin Care 2006 0.75
86 Meeting report from the XV International AIDS Conference. Prevention. AIDS Clin Care 2004 0.75